Abraxis BioScience Inc. said Friday that chief financial officer David O'Toole was leaving the company. Rick Rodgers, a former finance executive at another pharmaceutical company, will replace him.

Abraxis, the Los Angeles developer of the cancer drug Abraxane, did not give a reason for the departure of O'Toole, who joined Abraxis in May 2008 after serving as a partner in the strategic client group of Deloitte & Touche LLP.

Rogers was controller and chief accounting officer at cancer drug maker MGI Pharma until that Bloomington, Minn. company was acquired by Japanese drug maker Eisai Co. last year.

Abraxis shares were down 43 cents, or 1 percent, to $32.98 in midday trading on the Nasdaq.